Katherine E Lewis

USPTO Granted Patents = 19 (Patent Applications = 12)

CIPO Patents = 1 (Patent Applications = 6)

EPO Patents = 5 (Patent Applications = 14)

Average Co-Inventor Count = 6.0

ph-index = 8

Forward Citations = 197(Granted Patents)

Location History:

Seattle, WA (US) (2014)
Lake Forest Park, WA (US) (2007 - 2023)

Company Filing History:

Bristol-myers Squibb Compnay

patents

5 out of 71

Five Prime Therapeutics, Inc.

patents

where one patent can have more than one assignee

Years Active: 2007-2023

Loading Chart...

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11566076 - Anti-CSF1R antibody and anti-PD-1 antibody combination therapy for selected cancers (2023-01-31),

2. 11421034 - Combination anti-CSF1R and anti-PD-1 antibody combination therapy for pancreatic cancer (2022-08-23),

3. 11274152 - Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors (2022-03-15),

4. 10618967 - Anti-CSF1R antibody and anti PD-1 antibody combination therapy for cancer (2020-04-14),

5. 10562967 - Treating inflammation with IL-17/IL-23 bispecific antibodies (2020-02-18),

6. 10221244 - Anti-CSF1R antibody and anti PD-1 antibody combination therapy for cancer (2019-03-05),

7. 10081681 - Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors (2018-09-25),

8. 9994634 - Use of an IL-17/IL-23 bispecific antibody for treating inflammation (2018-06-12),

9. 9765147 - Anti-CSFR1 antibody and anti PD-1 antibody combination therapy for cancer (2017-09-19),

10. 9464134 - Polynucleotides encoding antagonists of IL-17A, IL-17F, and IL-23p19 (2016-10-11),

11. 8992922 - Antagonists of IL-17A, IL-17F, and IL-23P19 (2015-03-31),

12. 8822642 - Dimeric fusion proteins and related compositions and methods (2014-09-02),

13. 8496936 - Antagonists of IL-17A, IL-17F, and IL-23P19 (2013-07-30),

14. 8333968 - Methods of inhibiting inflammation with antagonists to IL-17A, IL-17F, and IL-23P19 (2012-12-18),

15. 8227579 - IL-23 antagonists (2012-07-24),

Title: Katherine E. Lewis: Innovator in Cancer Therapeutics

Introduction

Katherine E. Lewis is an accomplished inventor based in Seattle, WA, with a notable portfolio comprising 19 patents. Her innovative contributions focus on novel therapeutic approaches for cancer treatment, particularly involving antibody therapies.

Latest Patents

Katherine's latest patents include advancements in combination therapies for cancer treatment. One of her key inventions is the "Anti-CSF1R antibody and anti-PD-1 antibody combination therapy for selected cancers," which outlines methods of using antibodies that bind to the colony stimulating factor 1 receptor (CSF1R) in conjunction with PD-1/PD-L1 inhibitors. Another significant patent focuses on methods for treating pancreatic cancer using "combination anti-CSF1R and anti-PD-1 antibody combination therapy," detailing specific dosage regimens of antibodies like cabiralizumab and nivolumab.

Career Highlights

Throughout her career, Katherine has had the opportunity to work with several leading companies in the biotechnology field, including Zymogenetics, Inc. and Bristol-Myers Squibb Company. Her work has significantly advanced the understanding and treatment of cancer through innovative antibody therapies.

Collaborations

Katherine has collaborated with several esteemed colleagues, including Steven D. Levin and Scott R. Presnell. These partnerships have been pivotal in furthering research and development in cancer therapeutics.

Conclusion

Katherine E. Lewis's contributions to the field of cancer treatment exemplify the impact of innovation and invention in medicine. Her unique approach to combining antibody therapies marks a significant step forward in the fight against cancer, demonstrating the essential role inventors play in advancing healthcare solutions.

This text is generated by artificial intelligence and may not be accurate.